Trial Profile
Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms EU OPTILIV trial; OPTILIV
- 17 Aug 2017 Results (n=52) of pharmacogenetic assessment in OPTILIV published in the British Journal of Cancer
- 06 Jun 2017 Results of pharmacogenomic predictors of response and survival presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results assessing pharmacogenomic determinants presented at the 53rd Annual Meeting of the American Society of Clinical Oncology